SI-BONE, Inc. (SIBN) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $8.5M sold). Latest close $23.54 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 17, 2026 · Congress to Nov 16, 2026.
First Eagle Investment Management — 1 tracked fund hold SIBN. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 33 sales ($8.5M). Insider trading
BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| First Eagle Investment Management | 0.02% | 768,941 | ADDED (+20.3%) Q3 filed Nov 10 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +37.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 170 of 8,857 filers |
| Long-only filers among them | 168 |
| Change vs 2026 Q1 | -2 net · 164 entered · 166 exited |
| Shares reported, all filers | 47,423,972 |
| Reported value, all filers | $772.0M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus (SIC 3841) |
| Revenue · FY2025 | $200.9M |
| Net income · FY2025 | $-18.9M |
| Total assets · FY2025 | $238.6M |
| Shares outstanding | 44,818,575 |
| Market cap (at latest close) | $1.1B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 29, 2026.
| Shares short · Oct 15, 2026 | 4,704,576 |
| Share of shares outstanding | 10.50% |
| Days to cover | 8.67 |
Shares short at recent settlements — Jul 31, 2026: 5.1M · Aug 14, 2026: 5.3M · Aug 31, 2026: 5.6M · Sep 15, 2026: 5.9M · Sep 30, 2026: 5.1M · Oct 15, 2026: 4.7M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 29, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 29, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 33 sales by 4 insiders ($8.5M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | Maheshwari Anshul | Chief Op & Financial Officer | Sell | 1,715 | $23.19 | $39.8K | SEC filing |
| Nov 17, 2026 | FRANCIS LAURA | Chief Executive Officer | Sell | 1,901 | $23.18 | $44.1K | SEC filing |
| Nov 16, 2026 | Maheshwari Anshul | Chief Op & Financial Officer | Sell | 2,476 | $23.31 | $57.7K | SEC filing |
| Nov 16, 2026 | Maheshwari Anshul | Chief Op & Financial Officer | Sell | 2,189 | $23.34 | $51.1K | SEC filing |
| Nov 16, 2026 | PISETSKY MICHAEL A. | Chief Legal Officer | Sell | 1,854 | $23.32 | $43.2K | SEC filing |
| Nov 16, 2026 | PISETSKY MICHAEL A. | Chief Legal Officer | Sell | 1,871 | $23.31 | $43.6K | SEC filing |
| Nov 16, 2026 | FRANCIS LAURA | Chief Executive Officer | Sell | 3,892 | $23.33 | $90.8K | SEC filing |
| Nov 16, 2026 | FRANCIS LAURA | Chief Executive Officer | Sell | 2,235 | $23.33 | $52.1K | SEC filing |
| Nov 16, 2026 | FRANCIS LAURA | Chief Executive Officer | Sell | 3,203 | $23.32 | $74.7K | SEC filing |
| Nov 16, 2026 | FRANCIS LAURA | Chief Executive Officer | Sell | 3,651 | $23.33 | $85.2K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | ANSHUL MAHESHWARI | Officer | 1,731 | $31.3K | Oct 5, 2026 | SEC filing |
| Aug 24, 2026 | ANSHUL MAHESHWARI | Officer | 11,636 | $232.3K | Aug 24, 2026 | SEC filing |
| Aug 24, 2026 | DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003 | Director, Officer | 25,972 | $518.4K | Aug 24, 2026 | SEC filing |
| Aug 21, 2026 | DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003 | Director, Officer | 3,923 | $76.4K | Aug 21, 2026 | SEC filing |
| Aug 21, 2026 | ANSHUL MAHESHWARI | Officer | 11,228 | $218.7K | Aug 21, 2026 | SEC filing |
| Aug 20, 2026 | DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003 | Director, Officer | 51,884 | $1.0M | Aug 20, 2026 | SEC filing |
| Aug 19, 2026 | ANSHUL MAHESHWARI | Officer | 5,747 | $110.0K | Aug 19, 2026 | SEC filing |
| Aug 3, 2026 | THE JEFFREY W DUNN LIVING TRUST DTD 05/17/2012 | Director | 80,000 | $1.4M | Aug 3, 2026 | SEC filing |
| May 29, 2026 | TIMOTHY E DAVIS JR | Director | 3,500 | $49.5K | May 29, 2026 | SEC filing |
| Mar 12, 2026 | MIKA NISHIMURA | Director | 4,100 | $56.7K | Mar 12, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Cadian Capital Management, LP | SC 13G | 3,347,574 | 7.5% | Jun 30, 2026 | SEC filing |
| Jul 30, 2026 | BlackRock, Inc. | SC 13G/A | 3,558,735 | 8.0% | Jun 30, 2026 | SEC filing |
| May 7, 2026 | First Light Asset Management, LLC | SC 13G/A | 7,971,486 | 18.0% | Apr 30, 2026 | SEC filing |
| Apr 24, 2026 | BlackRock, Inc. | SC 13G/A | 3,057,039 | 6.9% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 17, 2026 | OrbiMed Capital LLC | SC 13G/A | 0 | 0.0% | Dec 31, 2025 | SEC filing |
| Feb 13, 2026 | BROWN ADVISORY INC | SC 13G/A | 2,513,268 | 5.8% | Dec 31, 2025 | SEC filing |
| Feb 13, 2026 | American Century Mutual Funds, Inc. | SC 13G/A | 1,779,575 | 4.1% | Dec 31, 2025 | SEC filing |
| Feb 12, 2026 | Champlain Investment Partners, LLC | SC 13G | 2,108,944 | 4.9% | Sep 30, 2025 | SEC filing |
| Dec 5, 2025 | First Light Asset Management, LLC | SC 13G | 5,046,068 | 11.6% | Nov 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 15 Lobbying Disclosure Act filings named this company as client, 2017–2025; most common issues: Health Issues (14), Medical/Disease Research/Clinical Labs (10), Taxation/Internal Revenue Code (5).
Federal contracts: $383.0K in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $69.6K |
| FY2022 | $91.7K |
| FY2023 | $67.2K |
| FY2024 | $91.3K |
| FY2025 | $63.1K |
| FY2026 | $0 |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 36C25225P0293 | Department of Veterans Affairs | $23.1K | Feb 5, 2025 |
| 36C25224P0505 | Department of Veterans Affairs | $23.1K | Mar 21, 2024 |
| 36C25223P0636 | Department of Veterans Affairs | $23.1K | Apr 20, 2023 |
| 36C26121P1213 | Department of Veterans Affairs | $22.9K | Jun 29, 2021 |
| 36C24625P0674 | Department of Veterans Affairs | $15.4K | Feb 11, 2025 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Gross Profitability (Novy-Marx) — High gross profit relative to total assets
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Growth — Latest revenue: $200.9M · 5-yr revenue CAGR: 22.3% · Straight growth years: 6
· Gross Profitability (Novy-Marx) — Gross profit / assets: 67.0% · Gross margin: 79.6%
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold SIBN — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 2, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Sep 11, 2026 | 1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 3, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on SIBN
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.